Latest Research And Development News

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Aurora Labs has completed the design and initial testing of its AU4 40kg thrust micro gas turbine, marking a significant step in UAV propulsion technology. The company is now focusing on scaling production and deepening defence sector partnerships following strong international engagement.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Li-S Energy Limited reported solid progress in its March 2025 quarter, advancing a key collaboration with Kea Aerospace to integrate lithium-sulfur batteries into high-altitude UAVs, while strengthening its board and maintaining a healthy cash position.

Visionflex Group Limited reported a net cash outflow of AUD 1.34 million for Q1 2025, maintaining liquidity through convertible note facilities that extend funding runway to over two quarters.

Amplia Therapeutics has completed recruitment early for its Phase 2a ACCENT trial in advanced pancreatic cancer, reporting encouraging interim results and advancing a second trial with FDA-backed protocol changes.

BauMart Holdings Limited has announced a rights issue to raise approximately $482,000 by offering new shares at a steep discount, aiming to accelerate equipment delivery, fund R&D, and support international recruitment.

Hammer Metals Limited reported significant progress in its March 2025 quarter, highlighting promising drilling results at Lady Jenny and Mount Mascotte, alongside ongoing joint venture activities and a solid financial position.

BauMart Holdings has unveiled a multi-pronged strategy to tackle construction labour shortages, advance green building materials, and expand mining equipment services, supported by a $482,000 rights issue.